The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Fueling Open‐Source Drug Discovery: 177 Small‐Molecule Leads against Tuberculosis
Open accessAbstract
With the aim of fuelling open‐source, translational, early‐stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible. A set of 177 potent non‐cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compounds toward a chemical genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead‐generation activities. Two additional drug‐discovery‐relevant datasets are included: a) a drug‐like property analysis reflecting the latest lead‐like guidelines and b) an early lead‐generation package of the most promising hits within the clusters identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Thousands of chemical starting points for antimalarial lead identification
Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., Vanderwall, D. E., Green, D. V. S., Kumar, V., Hasan, S., et al. (2010) · Nature · doi:10.1038/nature09107 · Cited by 996
Self-citationThe complete genome sequence of Mycobacterium bovis
Garnier, T., Eiglmeier, K., Camus, J.-C., Medina, N., Mansoor, H., Pryor, M., Duthoy, S., Grondin, S., Lacroix, C., Monsempe, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1130426100 · Cited by 955
Butina, D. (1999) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci9803381 · Cited by 601
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442
Wright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S. R., Feldman, K., Hoffner, S., Drobniewski, F., Barrera, L., van Soolingen, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60331-7 · Cited by 385
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Self-citationHigh-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv
Ananthan, S., Faaleolea, E. R., Goldman, R. C., Hobrath, J. V., Kwong, C. D., Laughon, B. E., Maddry, J. A., Mehta, A., Rasmussen, L., Reynolds, R. C., et al. (2009) · Tuberculosis · doi:10.1016/j.tube.2009.05.008 · Cited by 279
Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity
Hill, A. P., & Young, R. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.016 · Cited by 258
Self-citationMoraski, G. C., Markley, L. D., Hipskind, P. A., Boshoff, H., Cho, S., Franzblau, S. G., & Miller, M. J. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200036r · Cited by 184
Antituberculosis activity of the molecular libraries screening center network library
Maddry, J. A., Ananthan, S., Goldman, R. C., Hobrath, J. V., Kwong, C. D., Maddox, C. B., Rasmussen, L. A., Reynolds, R. C., Secrist, J. A. I., Sosa, M. I., et al. (2009) · Tuberculosis · doi:10.1016/j.tube.2009.07.006 · Cited by 151
Mak, P. A., Rao, S. P. S., Tan, M. P., Lin, X., Chyba, J., Tay, J. A., Ng, S. H., Tan, B. H., Cherian, J., Duraiswamy, J., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb2004884 · Cited by 121
Unfinished business: target-based drug discovery
Brown, D. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.017 · Cited by 98
Goldman, R., & Gabriel, R. P. (2005) · Elsevier eBooks · doi:10.1016/b978-155860889-4/50004-5 · Cited by 70
Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis
Rullás, J., García, J. I., Beltrán, M., Cardona, P.-J., Cáceres, N., Garcia-Bustos, J., & Angulo‐Barturen, Í. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01423-09 · Cited by 69
Challenges and Opportunities in Developing Novel Drugs for TB
Kaneko, T., Cooper, C. B., & Mdluli, K. E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.115 · Cited by 66
Animal Models of Mycobacteria Infection
Ordway, D. J., & Orme, I. M. (2011) · Current Protocols in Immunology · doi:10.1002/0471142735.im1905s94 · Cited by 51
Discovery and validation of new antitubercular compounds as potential drug leads and probes
Goldman, R. C., & Laughon, B. E. (2009) · Tuberculosis · doi:10.1016/j.tube.2009.07.007 · Cited by 35
Multidrug- and extensively drug-resistant tuberculosis: an emerging threat
Berry, M. P. R., & Kon, O. M. (2009) · European Respiratory Review · doi:10.1183/09059180.00005209 · Cited by 29
The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry?
Young, R. J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.119 · Cited by 21
Self-citation
Cited by
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492
Extending the Applicability of the ANI Deep Learning Molecular Potential to Sulfur and Halogens
Devereux, C., Smith, J. S., Huddleston, K. K., Barros, K., Zubatyuk, R., Isayev, O., & Roitberg, A. E. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.0c00121 · Cited by 441
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
Information retrieval and text mining technologies for chemistry
Krallinger, M., Rabal, O., Lourenço, A., Oyarzabal, J., & Valencia, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00851 · Cited by 281
Metadata
- Authors
- Ballell, L., Bates, R. H., Young, R. J., Alvarez‐Gomez, D., Alvarez‐Ruiz, E., Barroso, V., Blanco, D., Crespo, B., Escribano, J., González, R., Lozano, S., Huss, S., Santos‐Villarejo, A., Martín‐Plaza, J. J., Mendoza, A., Rebollo‐Lopez, M. J., Remuiñan‐Blanco, M., Lavandera, J. L., Pérez‐Herran, E., Gamo‐Benito, F. J., García‐Bustos, J. F., Barros, D., Castro, J. P., & Cammack, N.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2013-01-10
- Volume
- 8
- Issue
- 2
- Pages
- 313-321
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2034080889
- Cited by
- 308
- References
- 23
- FWCI
- 31.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.